Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

8.49USD
20 Apr 2018
Change (% chg)

$0.03 (+0.35%)
Prev Close
$8.46
Open
$8.43
Day's High
$8.60
Day's Low
$8.21
Volume
20,531
Avg. Vol
45,930
52-wk High
$39.85
52-wk Low
$7.41

Latest Key Developments (Source: Significant Developments)

Merrimack Provides Business Update And Reports 2017 Financial Results
Monday, 12 Mar 2018 06:27am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS.‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​.‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​.MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​.MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019.Q4 LOSS PER SHARE $0.89.  Full Article

Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
Monday, 12 Mar 2018 06:25am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER.MERRIMACK PHARMACEUTICALS INC - ‍RANDOMIZED PHASE 2 STUDY ACCRUAL RAISED TO 100 PATIENTS; DATA STILL EXPECTED LATER THIS YEAR​.MERRIMACK PHARMACEUTICALS INC - ‍MERRIMACK CONTINUES TO ANTICIPATE TOP-LINE DATA FROM SHERLOC STUDY IN SECOND HALF OF 2018​.  Full Article

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 04:40pm EST 

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Merrimack reports Q3 loss per share from continuing operations $0.40
Wednesday, 8 Nov 2017 06:40am EST 

Nov 8 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports third quarter 2017 financial results.Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40.Merrimack Pharmaceuticals-Believes unrestricted cash & cash equivalents & payments from shire will be sufficient to fund operations into H2 2019.  Full Article

Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
Monday, 30 Oct 2017 06:55am EDT 

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer.Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​.Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​.  Full Article

Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes
Friday, 13 Oct 2017 07:30am EDT 

Oct 13 (Reuters) - Merrimack Pharmaceuticals Inc ::Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020.Merrimack Pharmaceuticals-commenced tender offer to buy $25.03 million aggregate principal amount of outstanding 4.50 pct convertible senior notes due 2020​.  Full Article

Merrimack announces settlement of convertible note litigation
Tuesday, 10 Oct 2017 04:24pm EDT 

Oct 10 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack announces settlement of convertible note litigation.Merrimack Pharmaceuticals Inc - ‍agreement resolves outstanding litigation associated with Merrimack's asset sale to Ipsen​.Merrimack - ‍agrees to commence tender offer to purchase outstanding convertible notes with potential to eliminate all remaining debt​.Merrimack Pharmaceuticals Inc - Merrimack does not intend to declare an additional special dividend with any funds from escrow​.Merrimack-Under terms of settlement,co to pay noteholder plaintiffs $0.90 per $1.00 of convertible notes,plus accrued interest,an amount for legal fees​.Merrimack Pharmaceuticals -tender offer to acquire all remaining convertible notes at rate $0.90 per $1.00 of convertible notes, plus accrued interest​.Merrimack -‍settlement payout,amount co expects to pay for remaining notes,expenses related to Delaware action to be about $60 million released from escrow​.  Full Article

Merrimack announces date of one-for-ten reverse stock split
Thursday, 31 Aug 2017 08:00am EDT 

Aug 31 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack announces date of one-for-ten reverse stock split.Merrimack Pharmaceuticals Inc says ‍one-for-ten reverse stock split- shares of common stock will begin trading on split-adjusted basis on September 6​.  Full Article

Merrimack Pharmaceuticals names Jean Franchi CFO
Monday, 14 Aug 2017 06:55am EDT 

Aug 14 (Reuters) - Merrimack Pharmaceuticals Inc :Names ‍jean Franchi as chief financial officer​.Merrimack Pharmaceuticals Inc - ‍appointment of Jean M. Franchi as chief financial officer, effective August 21, 2017​.  Full Article

Merrimack reports Q2 loss per share $0.22
Wednesday, 9 Aug 2017 06:55am EDT 

Aug 9 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports second quarter 2017 financial results.Q2 loss per share $0.22.Merrimack - continues to believe cash, cash equivalents as of june 30, potential milestone payments, to be sufficient to fund operations into H2 2019​.  Full Article